BofA lowered the firm’s price target on Hologic to $86 from $94 and keeps a Neutral rating on the shares after the company reported Q3 results, raised FY23 guidance and gave initial color on FY24. The firm has lowered its FY23-25 revenue estimates due to more conservative core growth assumptions, but notes that its adjusted EPS estimates do not change significantly due to lower share assumptions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HOLX: